CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro

BACKGROUND: CAR T-cell therapy has been recently unveiled as one of the most promising cancer therapies in hematological malignancies. However, solid tumors mount a profound line of defense to escape immunosurveillance by CAR T-cells. Among them, cytokines with an inhibitory impact on the immune sys...

Descripción completa

Detalles Bibliográficos
Autores principales: Alishah, Khadijeh, Birtel, Matthias, Masoumi, Elham, Jafarzadeh, Leila, Mirzaee, Hamid Reza, Hadjati, Jamshid, Voss, Ralf-Holger, Diken, Mustafa, Asad, Sedighe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627098/
https://www.ncbi.nlm.nih.gov/pubmed/34838059
http://dx.doi.org/10.1186/s12967-021-03146-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627098/
https://www.ncbi.nlm.nih.gov/pubmed/34838059
http://dx.doi.org/10.1186/s12967-021-03146-0

Ejemplares similares